Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Size counts: From less than or equal to 1-cm to less than or equal to 5-cm tumor size, every centimeter has prognostic impact and separates into different T categories, and tumors greater than 5 cm but less than 7 cm are now T3; and those greater than 7 cm are now T4.
Distance to carina does not count: Tumors with endobronchial location less than 2 cm from the carina have similar outcomes to those greater than 2 cm from the carina.
N status remains largely the same.
An oligometastasis is now classified as M1b.
Descriptors for same lobe as well as other lobe intrapulmonary nodules as metastases or synchronous primary lesions are delineated.
Part-solid adenocarcinoma size will be defined by the size of the solid component on computed tomography and of the invasive component on microscopic examination.
The tumor, node, and metastasis (TNM) classification of malignant tumors is promulgated by the Union for International Cancer Control and the American Joint Committee on Cancer. The TNM classification undergoes periodical revisions based on the reports from the National TNM Committees and on the annual assessment of original articles. For the latest two editions of the TNM classification of lung cancer (7th edition of 2009 and 8th edition of 2016), the revisions were based on two international databases collected by the International Association for the Study of Lung Cancer (IASLC). These databases were stored, managed, and analyzed by Cancer Research And Biostatistics, a not-for-profit data center based in Seattle, WA, USA, in collaboration with the members of the IASLC Staging and Prognostic Factors Committee. This chapter presents the process of revision leading to the eighth edition of the TNM classification of lung cancer, the innovations introduced, and their clinical implications. The eighth edition of the TNM classification of malignant tumors will be enacted on January 1, 2017.
For the second consecutive time, the IASLC registered data from around 100,000 patients with lung cancer. For this revision, the period of diagnosis was from 1999 to 2010. Data originated in 35 different databases in 16 countries of 5 continents. Their geographical origin and number of patients are as follows: Europe, 46,560; Asia, 41,705; North America, 4660; Australia, 1593; and South America, 190, for a total of 94,708 patients. After exclusions, 77,156 patients met the requirements for analysis: 70,967 with nonsmall cell lung cancer (NSCLC) and 6189 with SCLC. Table 25.1 shows the type of databases contributing to the IASLC Staging Project and the nature of the data. Most data were retrospective, that is, contributors around the world already were registering data on patients with lung cancer and submitted their databases to the IASLC. These databases contained the minimum information regarding TNM descriptors, but some of them lacked the necessary detail needed for deeper analyses. By contrast, data registered through the electronic data capture online system are smaller in numbers but richer in detail and were useful, for example, to analyze the descriptors of the M component because they contained the information on number and location of metastases. Table 25.2 shows the type of treatment undergone by the registered patients with SCLC and NSCLC. The proportion of patients treated with tumor resection either alone or in combination with chemotherapy and/or radiotherapy is higher in this database than in the one used for the seventh edition. This is due to the fact that databases of clinical trials, usually collected for advanced disease, were not submitted. However, surgical registries have complete information on the descriptors of the anatomic extent of the disease and are readily available for analysis. Despite this lack of patients with advanced lung cancer, all findings potentially leading to recommendations for changes were validated in the populations of patients with clinically and pathologically staged tumors, except those of the M component that were exclusively based on clinically staged tumors.
Type of Database | Retrospective | Prospective (EDC) | Total |
---|---|---|---|
Consortium | 41,548 | 2089 | 43,637 |
Registry | 26,122 | 26,122 | |
Surgical series | 5373 | 592 | 5965 |
Institutional series | 1185 | 1185 | |
Institutional registries | 208 | 208 | |
Unknown | 39 | 39 | |
Total | 73,251 | 3905 | 77,156 |
Treatment Modality | % |
---|---|
Surgery alone | 57.7 |
Chemotherapy and surgery | 21.1 |
Radiotherapy and surgery | 1.5 |
Trimodality | 4.4 |
Chemotherapy alone | 9.3 |
Chemotherapy and radiotherapy | 4.7 |
Radiotherapy alone | 1.5 |
The T component of the classification is complex to analyze because it has many descriptors: tumor size, endobronchial location, atelectasis/pneumonitis, and invasion of various anatomic structures surrounding the lung. For their analyses, the prognostic impact of each descriptor was analyzed individually in five different populations of patients: three with pathologically staged tumors (pT1–4 N0 M0 completely resected [R0]; pT1–4 any N M0 R0; and pT1–4 any N M0 any R, i.e., including resections with microscopic [R1] and macroscopic [R2] evidence of residual tumor) and two with clinically staged tumors (cT1–4 N0 M0 and cT1–4 any N M0). Additional univariate and multivariate analyses were performed after adjustment by histopathologic type, geographical region of origin, age, and sex. These analyses generated multiple survival curves that were closely analyzed to see if the different descriptors were properly assigned to their T category. The results of these analyses can be summarized as follows:
The 3-cm landmark still separates T1 from T2 tumors.
Tumor size, analyzed at 1-cm intervals, has more prognostic impact than previously shown in past editions of the TNM classification. From less than or equal to 1-cm to less than or equal to 5-cm tumor size, every centimeter counts and separates different T categories.
The prognosis of tumors greater than 5 cm to less than or equal to 7 cm was similar to that of T3 tumors.
The prognosis of tumors greater than 7 cm was similar to that of T4 tumors.
The prognosis of tumors with endobronchial location less than 2 cm from the carina (a T3 descriptor in the 7th edition) was found to be similar to that of their T2 counterparts (endobronchial location >2 cm from the carina).
The prognosis of tumors with total atelectasis/pneumonitis (a T3 descriptor in the 7th edition) was found to have a T2 prognosis, similar to that of tumors with partial atelectasis/pneumonitis.
The prognosis of tumors with invasion of the diaphragm (a T3 descriptor in the 7th edition) was found to be similar to that of T4 tumors.
The invasion of the mediastinal pleura was rarely used as a unique descriptor.
Based on the aforementioned findings, the recommendations for changes in the T categories are as follows:
Subdivide T1 into three new subcategories: T1a (≤1 cm), T1b (>1 cm but ≤2 cm), and T1c (>2 cm but ≤3 cm).
Subdivide T2 into two new subcategories: T2a (>3 cm but ≤4 cm) and T2b (>4 cm but ≤5 cm).
Reclassify tumors greater than 5 cm but less than or equal to 7 cm as T3.
Reclassify tumors greater than 7 cm as T4.
Reclassify tumors with endobronchial location less than or equal to 2 cm from the carina, but without involvement of the carina, as T2.
Reclassify tumors with total atelectasis/pneumonitis as T2.
Reclassify tumors with invasion of the diaphragm as T4.
Delete the invasion of the mediastinal pleura as a descriptor.
When survival is analyzed according to these new T descriptors, survival curves separate well and do not cross over. All survival differences are significant and there is a clear difference between T3 and T4 that was not seen in the seventh edition ( Fig. 25.1 ).
Visceral pleural invasion, defined as the invasion of its elastic layer, is well assigned to the T2 category ( Fig. 25.2 ). There are survival differences between PL1 and PL2, but these are only identifiable at pathologic staging, so they cannot be used to modify the present T2 descriptor based on the extent of visceral pleural invasion. However, they are useful to refine postoperative prognosis in those patients with resected tumors in which visceral pleural invasion is identified. Because visceral pleura involvement impacts prognosis, the use of elastic stains is emphasized again in the eighth edition of the TNM classification of lung cancer, if it is not evident on hematoxylin and eosin stains.
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here